Investing.comDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 19:12:42·⟳ 抓取 19:13:20 +38s·⚡ 决策 10-21 19:15:21 +2m01s·6.4 天前
Invivyd在IDWeek 2026展示在研麻疹单抗VMS063临床前体外中和数据
本条Investing.com稿件（11:12 UTC）是9分钟前（11:05 UTC）已决策的公司通稿同一事件的AI改写稿，事实集合完全一致、无任何新增信息；VMS063仍处于纯临床前阶段（无人体数据、未提交IND、2027年才拟进临床），项目本身2026年4月已通过8-K公开，无状态迁移与近期业绩弹性，不构成可交易催化。
📄 原文Investing.com↗ 原文
Invivyd presents preclinical data on measles antibody candidate
SpaceX, Tesla shares rise after Musk says committees exploring possible merger NEW HAVEN, Conn. - Invivyd, Inc. (NASDAQ…
不做 Invivyd, Inc.（IVVD.US）
重复消息：Investing.com改写稿与72小时内（9分钟前）已决策的公司通稿为同一事件、无新增事实；内容为纯临床前体外数据，无IND/人体数据/监管里程碑，项目2026年4月已公开，无状态迁移；标的为0.64美元仙股、盘前仅约3千股、流动性极差，做多无edge；事件正面且无强空催化，亦不做空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Invivyd在IDWeek展示的麻疹单抗VMS063仅为临床前体外数据，无监管/临床里程碑，且项目今年4月已披露、同一通稿72小时内刚被本臂判为不做；美股盘前仅约3千股微涨3.7%，流动性极差，多空均无edge。
🔎 新鲜度:最早出现 2026-04-09 · 扩散 medium · price-in 风险 high ↗
关键理由
- 数据为纯体外临床前结果，距IND和人体验证尚远（2027年才拟进临床），无近期收入或估值催化
- VMS063项目已于2026年4月通过公司新闻稿及SEC 8-K公开，本次会议展示无新增状态迁移
主要风险
- 小市值仙股（约1.88亿美元市值、股价0.64美元）易受会议新闻驱动出现低流动性脉冲，但盘前成交量极小、无持续性依据
- Investing.com稿件标题与正文不符（误植SpaceX/Tesla合并），系AI生成模板错误，增加信息噪音但不改变事件实质
反向证据
- 做多前查反向 · 来源 search_processed_events · 日期 2026-10-21 · 影响 invalidates
已处理记录核实：数据纯临床前、无人体数据、未提交IND、2027年才拟进临床，且项目2026年4月已8-K披露——无近期催化，削弱做多
检索:Invivyd VMS063 measles IND clinical 2026
先例如何影响了这次决策
对本次决策的影响:未改变结论：与已处理记录一致AVOID
方向:事件因重复且无状态迁移早停，未再构建外部先例面板；生物医药经验明确：临床前体外数据不构成临床/监管状态迁移，距收入兑现至少数年
涨幅量级:无足够高相似对齐先例，不用任何涨幅校准交易参数
形态:未系统检索先例；不复用记忆中的案例
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 3,879 ms
{"result": "search_processed_events:agent query=`invivyd vms063 measles monoclonal antibody preclinical data idweek 2026 | invivyd 麻疹 单抗 临床前数据 | ivvd measles antibody idweek presentation`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.9/72 小时、22190 条本臂决策(完整)，返回 1 条候选。\n• 10-21 11:05 UTC(北京 19:05) [bm25:84%] 不做 IVVD.US - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 成功 stock_tools HTTP · 861 ms
{
原文全文
展开原文 · 2,078 字
SpaceX, Tesla shares rise after Musk says committees exploring possible merger
NEW HAVEN, Conn. - Invivyd, Inc. (NASDAQ:IVVD) presented preclinical data on its investigational monoclonal antibody candidate VMS063 for measles at IDWeek 2026 in Washington, D.C. today, according to a press release statement.
The data showed in vitro antiviral activity against contemporary measles virus variants, including genotypes B3 and D8. VMS063 targets the measles fusion protein and is designed to prevent cell entry by stabilizing the protein’s pre-fusion conformation.
The company stated it has begun manufacturing scale-up toward clinical development in 2027. Invivyd plans to develop VMS063 in either intramuscular or subcutaneous forms.
There are currently no FDA-approved treatments for measles. The U.S. is experiencing elevated measles cases in 2026, with disease burden nearly double that seen in 2025 as of October, according to the company.
"Despite continued transmission of measles globally, and a reemergence in the United States, physicians who see measles patients have long lamented that there are no targeted approved treatments for measles," said Michael Mina, Chief Medical Officer and Chief Epidemiologist of Invivyd.
VMS063 was engineered using Invivyd’s antibody discovery platform. The company stated the candidate demonstrated potent neutralization activity against historical and contemporary measles variants in both authentic virus and pseudovirus neutralization assays.
Invivyd described VMS063 as a half-life-extended, high resistance barrier antibody candidate that could potentially be used for both treatment and prevention of measles.
IDWeek 2026 is taking place October 21-24 at the Walter E. Washington Convention Center in Washington, D.C. The meeting is organized by the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW HAVEN, Conn. - Invivyd, Inc. (NASDAQ:IVVD) presented preclinical data on its investigational monoclonal antibody candidate VMS063 for measles at IDWeek 2026 in Washington, D.C. today, according to a press release statement.
The data showed in vitro antiviral activity against contemporary measles virus variants, including genotypes B3 and D8. VMS063 targets the measles fusion protein and is designed to prevent cell entry by stabilizing the protein’s pre-fusion conformation.
The company stated it has begun manufacturing scale-up toward clinical development in 2027. Invivyd plans to develop VMS063 in either intramuscular or subcutaneous forms.
There are currently no FDA-approved treatments for measles. The U.S. is experiencing elevated measles cases in 2026, with disease burden nearly double that seen in 2025 as of October, according to the company.
"Despite continued transmission of measles globally, and a reemergence in the United States, physicians who see measles patients have long lamented that there are no targeted approved treatments for measles," said Michael Mina, Chief Medical Officer and Chief Epidemiologist of Invivyd.
VMS063 was engineered using Invivyd’s antibody discovery platform. The company stated the candidate demonstrated potent neutralization activity against historical and contemporary measles variants in both authentic virus and pseudovirus neutralization assays.
Invivyd described VMS063 as a half-life-extended, high resistance barrier antibody candidate that could potentially be used for both treatment and prevention of measles.
IDWeek 2026 is taking place October 21-24 at the Walter E. Washington Convention Center in Washington, D.C. The meeting is organized by the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
e4812892b1· 2026-10-21 19:15 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前